groupH’s strategic Market Access practice reports favourable payer views on novel long-acting injectables.
The Market Access team here at groupH, with permission from MedinCell, recently published a White Paper; revealing in-depth payers’ views on the prospects of value creation through novel long-acting injectables, the challenges associated with evidence generation, and the potential to translate value and evidence into favourable coverage decisions and pricing.
Long-acting injectables (LAIs) have been around for a long time, helping in many indications to address unmet needs such as medication adherence and administration convenience. They have proved successful in a diverse range of disease areas, such as schizophrenia, acromegaly, alcohol addiction and endometriosis pain. However, up until now, greater utilization of LAIs has been impaired by limitations to the traditional delivery systems. These limitations can be addressed by a new generation of LAIs.
The example of early strategic market access work that we describe here identifies business opportunities in this rapidly developing area. It also illustrates the specific complexities of payer/market access work and the impact these have on forecast assumptions. Our ‘real’ payer relationships, developed over many years, help us to gain clarity and prioritise potential business opportunities.
groupH’s strategic Market Access practice reports favourable payer views on novel long-acting injectables
As always, your views are very welcome. We look forward to hearing from you.